Marcela Valko-Rokytovská

Dr. Marcela Valko-Rokytovská

University of Veterinary Medicine and Pharmacy in Košice
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MVMarcela Valko-Rokytovská
Marcela Valko-Rokytovská
POPeter Očenáš
Peter Očenáš
ASAneta Salayová
Aneta Salayová
ZKZuzana Kostecká
Zuzana Kostecká
Breast cancer is the most common malignancy in women with high mortality. Sensitive and specific methods for the detection, characterization and quantification of endogenous steroids in body fluids or tissues are needed for the diagnosis, treatment and prognosis of breast cancer and many other diseases. At present, non-invasive diagnostic methods are gaining more and more prominence, which enable a relatively fast and painless way of detecting many diseases. Metabolomics is a promising analytical method, the principle of which is the study and analysis of metabolites in biological material. It represents a comprehensive non-invasive diagnosis, which has a high potential for use in the diagnosis and prognosis of cancers, including breast cancer. This short review focuses on the targeted metabolomics of steroid hormones, which play an important role in the development and classification of breast cancer. The most commonly used diagnostic tool is the chromatographic method with mass spectrometry detection, which can simultaneously determine several steroid hormones and metabolites in one sample. This analytical procedure has a high potential in effective diagnosis of steroidogenesis disorders. Due to the association between steroidogenesis and breast cancer progression, steroid profiling is an important tool, as well as in monitoring disease progression, improving prognosis, and minimizing recurrence.

Verified
Journal Article
Open access
PDF file
BHBeáta Hubková
Beáta Hubková
MVMarcela Valko-Rokytovská
Marcela Valko-Rokytovská
BČBeáta Čižmárová
Beáta Čižmárová
MZMarianna Zabavnikova
Marianna Zabavnikova
MMMária Mareková
Mária Mareková
ABAnna Birková
Anna Birková
(1) Background: Tryptophan metabolism is known to be one of the important mechanisms used by cancer to evade immune surveillance. Altered tryptophan metabolism was studied in patients with pigmented malignant melanoma confirmed histologically by the anatomic stage grouping for cutaneous melanoma using clinical staging on the basis of the Breslow thickness of the melanoma, the degree of spread to regional lymph nodes, and by the presence of distant metastasis. (2) Methods: Urinary tryptophan metabolites were detected by RP-HPLC method. (3) Results: In the present work, we provided evidence of altered metabolism of all tryptophan pathways in melanoma patients. (4) Conclusions: Knowledge of the shifted serotonin pathway toward DHICA formation and kynurenine pathway shifted toward NAD+ production could serve in the early detection of the disease and the initiation of early treatment of malignant melanoma.

1 January 2020 in Journal of Veterinary Science
Verified
Journal Article
Open access
MVMarcela Valko-Rokytovská
Marcela Valko-Rokytovská
POPeter Očenáš
Peter Očenáš
ASAneta Salayová
Aneta Salayová
RSRadka Staroňová
Radka Staroňová
ZKZuzana Kostecká
Zuzana Kostecká
Valko-Rokytovská M, et al. J Vet Sci. 2019 Oct;21:e23. https://doi.org/10.4142/jvs.2020.21.e23

1 January 2016 in Neoplasma
Verified
Journal Article
Closed access
MVMarcela Valko-Rokytovská
Marcela Valko-Rokytovská
KBK. Bruchata
K. Bruchata
JSJ. Simkova
J. Simkova
MMM. Milkovicova
M. Milkovicova
ZKZ. Kostecka
Z. Kostecka
Current trends in the treatment of malignant melanoma

Verified
Journal Article
Open access
PDF file
ABAnna Birková
Anna Birková
MVMarcela Valko-Rokytovská
Marcela Valko-Rokytovská
BHBeáta Hubková
Beáta Hubková
MZMarianna Zabavnikova
Marianna Zabavnikova
MMMária Mareková
Mária Mareková
Urine autofluorescence at 295 nm is significantly higher in patients with malignant melanoma at each clinical stage compared to the healthy group. The largest difference is in the early-stages and without metastases. With increasing stage, the autofluorescence at 295 nm decreases. There is also a significant negative correlation between autofluorescence and Clark classification. Based on our results, it is assumed that the way malignant melanoma grows also affects urinary autofluorescence.

16 May 2019 in Medicina
Verified
Journal Article
Open access
PDF file
MVMarcela Valko-Rokytovská
Marcela Valko-Rokytovská
BHBeáta Hubková
Beáta Hubková
ABAnna Birková
Anna Birková
JMJana Mašlanková
Jana Mašlanková
MSMarek Stupak
Marek Stupak
MMMária Mareková
Mária Mareková
Background and objectives: Melanin, which has a confirmed role in melanoma cell behaviour, is formed in the process of melanogenesis and is synthesized from tryptophan, L-tyrosine and their metabolites. All these metabolites are easily detectable by chromatography in urine. Materials and Methods: Urine samples of 133 individuals (82 malignant melanoma patients and 51 healthy controls) were analysed by reversed-phase high-performance liquid chromatography (RP-HPLC). The diagnosis of malignant melanoma was confirmed histologically. Results: Chromatograms of melanoma patients showed increased levels of 5,6-dihydroxyindole-2-carboxylic acid, vanilmandelic acid, homovanilic acid, tryptophan, 5-hydroxyindole-3-acetic acid, and indoxyl sulphate compared to healthy controls. Concentration of indoxyl sulphate, homovanilic acid and tryptophan were significantly increased even in the low clinical stage 0 of the disease (indoxyl sulphate, homovanilic acid and tryptophan in patients with clinical stage 0 vs. controls expressed as medium/ interquartile range in µmol/mmol creatinine: 28.37/15.30 vs. 5.00/6.91; 47.97/33.08 vs. 7.33/21.25; and 16.38/15.98 vs. 3.46/6.22, respectively). Conclusions: HPLC detection of metabolites of L-tyrosine and tryptophan in the urine of melanoma patients may play a significant role in diagnostics as well as a therapeutic strategy of melanoma cancer.